Therapy of autoimmune diseases: clinical trials and new biologics
- 1 December 2002
- journal article
- review article
- Published by Elsevier in Current Opinion in Immunology
- Vol. 14 (6) , 812-815
- https://doi.org/10.1016/s0952-7915(02)00397-7
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trialBritish Journal of Dermatology, 2002
- Immunomodulation by Interleukin-10 Therapy Decreases the Incidence of Relapse and Prolongs the Relapse-free Interval in PsoriasisJournal of Investigative Dermatology, 2002
- Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasisExpert Opinion on Biological Therapy, 2002
- Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosusBritish Journal of Haematology, 2002
- Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivoNature Immunology, 2001
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Control of rheumatoid arthritis by oral toleranceArthritis & Rheumatism, 2001
- Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2 Pathway and Normalization of Keratinocyte MaturationJournal of Investigative Dermatology, 2001
- Epidermolysis Bullosa Acquisita Treated with Basiliximab, an Interleukin-2 Receptor AntibodyActa Dermato-Venereologica, 2001
- Effects of Oral Administration of Type II Collagen on Rheumatoid ArthritisScience, 1993